Janux Therapeutics, Inc.

NASDAQ (USD): Janux Therapeutics, Inc. (JANX)

Last Price

48.21

Today's Change

-1.57 (3.15%)

Day's Change

46.55 - 50.05

Trading Volume

574,544

Overview

Market Cap

2 Billion

Shares Outstanding

51 Million

Avg Volume

930,248

Avg Price (50 Days)

36.23

Avg Price (200 Days)

16.52

PE Ratio

-36.52

EPS

-1.32

Earnings Announcement

10-May-2024

Previous Close

49.78

Open

49.95

Day's Range

46.55 - 50.055

Year Range

5.65 - 58.694

Trading Volume

574,544

Price Change Highlight

1 Day Change

-3.15%

5 Day Change

0.15%

1 Month Change

21.96%

3 Month Change

414.51%

6 Month Change

626.05%

Ytd Change

337.48%

1 Year Change

220.55%

3 Year Change

91.69%

5 Year Change

91.69%

10 Year Change

91.69%

Max Change

91.69%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment